Proximal PSA Predicts Prostate Cancer Metastasis Risk
PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.
Prostate And Other Male Cancers
Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk
A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.
PSA Testing in Controls of Screening Trial May Undermine Results
Over 15 years of follow-up, considerable proportion of men undergo prostate-specific antigen testing
Low-PSA, High-Grade Prostate Cancer Especially Lethal
Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.
Novel PSA Assay Improves Prostate Cancer Diagnosis
The new test, IsoPSA, measures all PSA isoforms in serum and more accurately discriminates high-grade cancer from benign disease.
PSA Surge With Abiraterone Has No Long-Term Impact on Outcome
Spike in PSA level after starting abiraterone does not affect progression-free or overall survival, study finds.
More Preclinical PCa, Progression Among Black Men
Also increased risk of progression to metastatic disease compared with the general population.
USPSTF Issues Draft PCa Screening Recommendations
The US Preventive Services Task Force now suggests decisions about PSA testing should be made on an individual basis for men aged 55 to 69.
Earlier vs Later Prostate Cancer Recurrence Characterized
Pathologic Gleason scores, positive surgical margin rates, and PSA doubling times differentiate earlier from later biochemical recurrence after radical surgery.
Many Men Lack Information on PSA Screening Pros, Cons
In 2014, 33.9% of men reported that their health care providers failed to communicate the benefits and risks of PSA-based screening, an increase from 2012.
